References
- 1. Stubbs MJ, Mouyis M, Thomas M. Deep vein thrombosis. BMJ 2018;360:k351
- 2. Harjola VP. Deep vein thrombosis. EBM Guidelines 2017.Article ID: ebm00108(005.040).
- 3. Wells PS, Anderson DR, Bormanis J et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997;350(9094):1795-8.
- 4. National Institute for Health and Care Excellence. Deep vein thrombosis. 2013. https://cks.nice.org.uk/deep-vein-thrombosis. Accessed 16.01.2019.
- 5. Mutschler M, Paffrath T, Wölfl C et al. The ATLS® classification of hypovolaemic shock: A well-established teaching tool on the edge? Injury 2014;45 Suppl 3:S35-8.
- 6. Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2013;20(5):437-44.
- 7. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. London: EMA, 2004 [online]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003123.pdf.
- 8. Sardar P, Chatterjee S, Herzog E et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol. 2014 Aug;30(8):888-97. doi: 10.1016/j.cjca.2014.04.015. Epub 2014 Apr 18.
- 9. Bromley A, Plitt A. A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism. Cardiol Ther. 2018;7(1):1-13.
- 10. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-52